Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11602955 | 0.84 | GABRA1 (0.47) | GABRA1GABRB2ALDH1A1KDM4EMAPT | |
| SCHEMBL31130510 | 0.82 | CA1 (0.53) | GABRA1GABRB2ALDH1A1KDM4EMAPT | |
| SCHEMBL7135448 | 0.82 | CA1 (0.53) | GABRA1GABRB2ALDH1A1KDM4EMAPT | |
| SCHEMBL3944635 | 0.80 | HPGD (0.49) | ALDH1A1KDM4EPOLBSMN1; SMN2HPGD | |
| SCHEMBL7809004 | 0.80 | MAPT (0.60) | GABRA1GABRB2ALDH1A1MAPTTDP1 | |
| SCHEMBL23748226 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ETDP1POLBSMN1; SMN2 | |
| SCHEMBL16149262 | 0.79 | ERN1 (0.44) | ALDH1A1KDM4EMAPTTDP1POLB | |
| SCHEMBL30593089 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4ETDP1POLBSMN1; SMN2 | |
| SCHEMBL30739961 | 0.79 | CA1 (0.57) | ALDH1A1KDM4EMAPTTDP1POLB | |
| SCHEMBL11293049 | 0.79 | CXCR5 (0.43) | ALDH1A1KDM4EMAPTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643960-B2 | Procaspase activating compounds | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| US-9522901-B2 | Compositions and methods including cell death inducers and procaspase activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522901-B2 | Compositions and methods including cell death inducers and procaspase activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-12-03 | — | — | US | disclosed |
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-03-13 | — | — | US | disclosed |
| US-8236789-B2 | 1-adamantyl azetidin-2-one derivatives and drugs containing same | KOWA COMPANY, LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2322505-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME | Kowa Company, Ltd. (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
| WO-2008134474-A2 | COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344452-A1 | PROCASPASE ACTIVATING COMPOUNDS | CASP3, CASP6, BAX | GABRA1 4262/4885GABRB2 3669/4885ALDH1A1 892/4885 |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD3B1, CYP46A1 | GABRA1 2835/4885GABRB2 3364/4885ALDH1A1 169/4885 |
| US-20140073609-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | CASP3, CASP6, CASP5 | GABRA1 4549/4885GABRB2 4547/4885ALDH1A1 2167/4885 |
| US-20110257398-A1 | Compositions and Methods Including Cell Death Inducers and Procaspase Activation | CASP3, CASP6, CASP5 | GABRA1 4549/4885GABRB2 4547/4885ALDH1A1 2167/4885 |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | GABRA1 4473/4885GABRB2 4458/4885ALDH1A1 926/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | GABRA1 4544/4885GABRB2 4001/4885ALDH1A1 1106/4885 |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, CASP6, CASP5 | GABRA1 4473/4885GABRB2 4458/4885ALDH1A1 926/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | GABRA1 4544/4885GABRB2 4001/4885ALDH1A1 1106/4885 |
| US-20120040995-A1 | DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS | CASP3, CASP6, CASP14 | GABRA1 3738/4885GABRB2 3610/4885ALDH1A1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.